3'-Ethynylcytidine is a nucleoside analog characterized by the presence of an ethynyl group at the 3' position of the cytidine molecule. This modification enhances its stability and bioavailability, making it a subject of interest in antiviral research, particularly against RNA viruses. The compound exhibits properties that allow it to interfere with viral replication by mimicking natural nucleosides, thus inhibiting RNA synthesis. Its structure includes a pyrimidine base (cytosine) linked to a ribose sugar, with the ethynyl group contributing to its unique reactivity and potential therapeutic applications. 3'-Ethynylcytidine has been studied for its efficacy in treating diseases such as hepatitis C and has shown promise in clinical settings. Additionally, its chemical stability and ability to evade degradation by cellular enzymes make it a valuable candidate for further development in antiviral therapies. Overall, 3'-Ethynylcytidine represents a significant advancement in the design of nucleoside analogs for medical applications.

3'-Ethynylcytidine

180300-43-0: Sb-596168, Tas-106, ECyd, 1-(3-C-Ethynyl-beta-D-ribofuranosyl)cytosine, 3'-C-ethynylcytidine, Ethynylcytidine

Cytidine, 3'-C-ethynyl-

Ethynylcytidine is a nucleoside analogue that inhibits topoisomerase II and topoisomerase IV, which are enzymes involved in DNA replication. The compound has been shown to be an effective antitumor agent for solid tumours and also has potential as a biomarker or drug transporter. Ethynylcytidine can inhibit the growth of platinum-resistant ovarian cancer cells in vitro by preventing the formation of chromosomal DNA and impairing cellular respiration. It also has anti-inflammatory properties, which may be due to its ability to inhibit the drug transporter P-glycoprotein.

Ethynylcytidine

Ethynylcytidine is a nucleoside antimetabolite.

CAS 180300-43-0: 3'-Ethynylcytidine

Cytidine, 3'-C-ethynyl-

Ref: IN-DA0021VU

Ethynylcytidine

Ref: 3D-FHA30043

Ethynylcytidine

Ref: TM-TQ0006